Declaration of Voting Results & Voting Rights Announcements • Jun 8, 2018
Declaration of Voting Results & Voting Rights Announcements
Open in ViewerOpens in native device viewer
Lyon, France, June 8, 2018 - 6pm CEST - Pursuant to the provisions of article L. 233-8 II of the French « Code de Commerce » and article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") charter ADOCIA SA, a French société anonyme (corporation), 115, avenue Lacassagne, 69003 Lyon, (Euronext Paris: FR0011184241 – ADOC) a clinical stage biopharmaceutical company focused on diabetes treatment with innovative formulations of approved proteins, releases its total number of outstanding shares as well as its voting rights as of May 31, 2018.
| Month | Date | Total number of outstanding shares |
Total number of theoretical voting rights (1) |
Total number of exercisable voting rights (2) |
|---|---|---|---|---|
| May | 05/31/2018 | 6 916 753 | 9 598 576 | 9 583 395 |
(1) The total number of theoretical voting rights (or "gross" voting rights) is used as the basis for calculating the crossing of shareholding thresholds. In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all shares to which voting rights are attached, including shares whose voting rights have been suspended.
(2) The total number of exercisable voting rights (or "net" voting rights) is calculated without taking into account the shares with suspended voting rights, in this case, shares held by the Company in the context of a liquidity agreement
Adocia is a clinical-stage biotechnology company that specializes in the development of innovative formulations of already-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Adocia's portfolio of injectable treatments for diabetes, featuring six clinical-stage products and two preclinical products, is among the largest and most differentiated of the industry. Adocia also recently expanded its portfolio to develop treatments for obesity and short bowel syndrome.
The proprietary BioChaperone® technological platform is designed to enhance the effectiveness and/or safety of therapeutic proteins while making them easier for patients to use. Adocia customizes BioChaperone to each protein for a given application. Adocia's clinical pipeline includes four novel insulin formulations for the treatment of diabetes: two ultra-rapid formulations of insulin analog lispro (BioChaperone Lispro U100 and U200), a combination of basal insulin glargine and rapid-acting insulin lispro (BioChaperone Combo), a rapid-acting formulation of human insulin (HinsBet U100), and a prandial combination of human insulin with amylin analog pramlintide (BioChaperone Pramlintide Insulin). It also includes an aqueous formulation of human glucagon (BioChaperone Glucagon) for the treatment of hypoglycemia. Additionally, Adocia develops two combinations of insulin glargine with GLP-1 receptor agonists (BioChaperone Glargine Dulaglutide and BioChaperone Glargine Liraglutide), a ready-to-use aqueous formulation of teduglutide (BioChaperone Teduglutide) and a ready-to-use combination of glucagon and GLP-1 RA (BioChaperone Glucagon GLP1), all of which are in preclinical development.
Adocia and Tonghua Dongbao recently entered a strategic alliance. In April 2018, Adocia granted Tonghua Dongbao licenses to develop and commercialize BioChaperone Lispro and BioChaperone Combo in China and other Asian and Middle-Eastern territories. The licensing included a \$50M upfront and up to \$85M development milestones, plus double-digit royalties on sales. In June 2018, Tonghua Dongbao agreed to manufacture and supply insulin lispro and insulin glargine to Adocia globally, excluding China.
Adocia aims to deliver "Innovative medicine for everyone, everywhere."
To learn more about Adocia, please visit us at www.adocia.com
| Adocia | Adocia Press Relations | Adocia Investor Relations |
|---|---|---|
| Gérard Soula | Europe | USA |
| Chairman and CEO | MC Services AG | The Ruth Group |
| [email protected] | Raimund Gabriel | Tram Bui |
| Ph. : +33 4 72 610 610 | [email protected] | [email protected] |
| Ph. : +49 89 210 228 0 | Ph.: +1 646 536 7035 | |
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.